EMBL Corporate Partnership Programme gets new member
Daiichi Sankyo looks forward to future collaborations
EMBL’s Corporate Partnership Programme (CPP) welcomed Daiichi Sankyo as an associate corporate partner in April.
Headquartered in Tokyo – with a European Research facility in Munich – the company focuses on developing and delivering innovative new medicines, alongside advanced drug discovery and delivery methodologies, which serve patients globally.
CPP members benefit from direct connection with EMBL’s world-leading molecular biology research, services, and technology development, and their support enables EMBL to provide additional training opportunities for the next generation of molecular biologists. Specifically, members support EMBL’s scientific training and conferences programme fellowships, as well as the scientific visitor programme, and participate in discussions of future conference topics and practical courses.
For more information on the EMBL CPP, visit the newly updated CPP website.
